New trade: Short BIDU; Oct $220 or $210 Put. (Stock stop $230) Biotech Alert: NVTA* ---------------------------------- Open Trade Stats Open Trades = 47 ("Open" = has not yet reached expiration.) Max Gains >200% = 7 (3 >400%) Max Gains >150% = 13 Max Gains >100% = 23 Max Gains >75% = 25 Max Gains >50% = 28 Max Gains >25% = 38 ---------------------------------- We got off to a rocky start May-Jun but the system is beginning to shine and its time to go all in. Although it is hard to quantify, the highest and best way to trade this system is to set and exit at an initial profit target on your options, while leaving a small position on for further gains (the "lottery ticket"). Those further gains can be at whatever higher profit level you like, although holding blindly into expiration is probably the least effective way to manage the lottery ticket. Any gain above 200% (3X your initial investment) is worthy of consideration for closing out any leftovers. If those extra gains start deteriorating in any significant way, just close them out. Based upon the numbers above, and considering that 10 of those 47 trades have been put on just over the past two weeks and are still early in unfolding, taking between 75%-100% (with about 50-60% stop) looks like the sweet spot of the system. New subscribers and more conservative traders should probably start exiting at +50%, (also leaving on a small "lottery ticket" position), and ratcheting that level up with growing confidence the system. OPEN TRADES TRADES BY RETURN *Invitae (NVTA) NVTA is a genetics stock that I follow and it triggered a Buy Signal today on a 15% jump to $15.58. Although it is not on our trading list, nor is it one of the two biotech's recommended in the Sep 8th Weekend Update, I thought Friday's action merited it being brought front and center as a 3rd biotech worthy of consideration. "Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders" - Yahoo Finance
